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ffects of Statin Therapy
n Arrhythmic Events and Survival
n Patients With Nonischemic Dilated Cardiomyopathy
effrey J. Goldberger, MD, FACC,* Haris Subacius, MA,* Andi Schaechter, RN,* Adam Howard, BA,*
onald Berger, MD, PHD, FACC,† Alaa Shalaby, MD, FACC,‡ Joseph Levine, MD,§
lan H. Kadish, MD, FACC,* for the DEFINITE Investigators
hicago, Illinois; Baltimore, Maryland; Pittsburgh, Pennsylvania; and Roslyn, New York
OBJECTIVES We sought to evaluate whether statins were associated with a survival benefit and significant
attenuation in life-threatening arrhythmias in patients with nonischemic dilated cardiomy-
opathy.
BACKGROUND Statins are associated with a reduction in appropriate implantable cardioverter-defibrillator
(ICD) therapy in patients with coronary artery disease and improved clinical status in
nonischemic dilated cardiomyopathy.
METHODS The effect of statin use on time to death or resuscitated cardiac arrest and time to arrhythmic
sudden death was evaluated in 458 patients enrolled in the DEFINITE (DEFIbrillators in
Non-Ischemic cardiomyopathy Treatment Evaluation) study. The effect of statin use on time
to first appropriate shock was analyzed only in the 229 patients who were randomized to ICD
therapy.
RESULTS The unadjusted hazard ratio (HR) for death among patients on versus those not on statin
therapy was 0.22 (95% confidence interval [CI] 0.09 to 0.55; p  0.001). When controlled
for statin effects, ICD therapy was associated with improved survival (HR 0.61; 95% CI 0.38
to 0.99; p  0.04). There was one arrhythmic sudden death in the 110 patients receiving
statin therapy (0.9%) versus 18 of 348 patients not receiving statins (5.2%; p  0.04). The
unadjusted HR for arrhythmic sudden death among patients on versus those not on statin
therapy was 0.16 (95% CI 0.022 to 1.21; p  0.08). The HR for appropriate shocks among
patients on versus those not on statin therapy was 0.78 (95% CI 0.34 to 1.82) after adjustment
for baseline differences in the two groups.
CONCLUSIONS Statin use in the DEFINITE study was associated with a 78% reduction in mortality. This
reduction was caused, in part, by a reduction in arrhythmic sudden death. These findings
should be confirmed in a prospective, randomized clinical trial. (J Am Coll Cardiol 2006;
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.05.05348:1228–33) © 2006 by the American College of Cardiology Foundation
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sydroxymethylglutaryl coenzyme A reductase inhibitors
statins) are known to have effects independent of their
holesterol-lowering effects, referred to as pleiotropic ef-
ects. These effects have been implicated in protection
gainst atrial fibrillation (1–3) and in clinical improvement
n patients with heart failure (4–6). Statins also have been
ssociated with a reduction in mortality in large-scale lipid
rials and a reduction in appropriate implantable cardioverter-
efibrillator (ICD) therapy in patients with coronary artery
isease (7–9). Whether they have a specific effect on
ife-threatening ventricular arrhythmias or whether their
ffects on reducing these arrhythmias are predominantly
ediated by an anti-ischemic effect is unknown. Of note,
ignificant improvements in clinical status have been noted
From the *Clinical Trials Unit, Bluhm Cardiovascular Institute, Northwestern
emorial Hospital, and the Division of Cardiology, Feinberg School of Medicine,
hicago, Illinois; †Johns Hopkins Hospital, Baltimore, Maryland; ‡VA Pittsburgh
ealthcare System, Pittsburgh, Pennsylvania; and the §Heart Center, St. Francis
ospital, Roslyn, New York. The DEFINITE study was funded by St. Jude Medical,
ylmar, California.f
Manuscript received February 14, 2006; revised manuscript received May 5, 2006,
ccepted May 15, 2006.n patients with nonischemic dilated cardiomyopathy
reated with statins (4–6,10). If the pleiotropic effects of
hese drugs have specific beneficial effects on either cardiac
unction or life-threatening ventricular arrhythmias, they
lso may be associated with a survival benefit in patients
ith nonischemic dilated cardiomyopathy. The aim of this
eport was to evaluate whether statins were associated
ith a survival benefit and significant attenuation in
ife-threatening arrhythmias in patients with nonisch-
mic dilated cardiomyopathy enrolled in the DEFINITE
DEFIbrillators in Non-Ischemic Cardiomyopathy
reatment Evaluation) study.
ETHODS
he DEFINITE trial is described in detail elsewhere (11).
n brief, the DEFINITE trial was a randomized, prospec-
ive investigator-initiated study. Inclusion criteria were: age
etween 21 and 80 years, nonischemic cardiomyopathy with
left ventricular ejection fraction (LVEF) 35%, history of
ymptomatic heart failure, and the presence of one of the
ollowing within the past six months; nonsustained ventric-
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oring and/or an average of 10 premature ventricular beats
er hour on a 24-h Holter monitor. Patients were excluded
rom enrollment if they had New York Heart Association
NYHA) functional class IV heart failure, were candidates
or an ICD, or had a permanent pacemaker. Each patient
as randomized to standard oral medical therapy for heart
ailure or standard oral medical therapy plus an ICD. The
rimary end point of the study was death from any cause. A
respecified secondary end point was sudden death from an
rrhythmia. The cause of death was determined by an events
ommittee whose members were unaware of the patients’
reatment assignments according to classification proposed by
pstein et al. (12). All shocks were reviewed by a separate
ommittee. Shocks were classified by the committee as appro-
riate if delivered for ventricular tachycardia or fibrillation.
In this trial, more than 85% of patients received beta-
lockers, and more than 90% received angiotensin-
onverting enzyme (ACE) inhibitors/angiotensin receptor
lockers. The DEFINITE study protocol did not specify
reatment for hypercholesterolemia, but these data were
ollected at enrollment, at the time of an arrhythmic event,
nd at study termination. Cholesterol levels were not
outinely collected from all study participants.
tatistical analysis. The baseline characteristics of the two
roups were compared with the use of two-sample t tests for
ontinuous variables and chi-square tests for categorical
ariables. The log-rank test was used to compare Kaplan-
eier survival curves in the 2 groups and the Cox propor-
ional hazards survival model was used to adjust for covari-
tes as well as estimate the hazard ratio (HR) and
orresponding 95% confidence intervals (CIs). All covariates
ere entered in the first step of the regression model using
forward stepwise method. Statin therapy status was
ntered in a separate step after the significant covariates had
een determined. The impact statin therapy had in addition
o the combined effect of all significant covariates was
valuated using a likelihood ratio test.
Three separate end point analyses were performed to
valuate the effect of statin therapy in this trial. In the first
nalysis, time to death or resuscitated cardiac arrest was
nalyzed. Sixty-eight deaths and 2 resuscitated cardiac
rrests took place during the trial for a total of 69 events in
his analysis (1 patient who had a resuscitated cardiac arrest
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
CHF  congestive heart failure
DEFINITE  DEFIbrillators in Non-Ischemic
cardiomyopathy Treatment Evaluation
HR  hazard ratio
ICD  implantable cardioverter-defibrillator
LVEF  left ventricular ejection fraction
NYHA  New York Heart Associationubsequently died—the patient was coded as having reached
I
fhe end point at the time of the first event). The second
nalysis used an end point of arrhythmic sudden death,
hich included 17 deaths that had been adjudicated by the
vents committee to be arrhythmic sudden deaths and two
esuscitated cardiac arrests. These two analyses were per-
ormed in all 458 patients in the trial. The final analysis
valuated time to first appropriate shock in the 229 patients
andomized to receive an ICD. One additional arrhythmic
eath is included as an end point in a patient whose ICD
id not discharge despite the appearance of a lethal ventric-
lar arrhythmia. Four patients who crossed over from the
CD group to the standard therapy group were censored
rom analysis at the time of crossover. The average number
f appropriate shocks experienced by 34 patients also was
ompared using the t test. All p values were 2-tailed; p 
.05 was considered significant.
ESULTS
our-hundred fifty-eight patients with nonischemic dilated
ardiomyopathy were enrolled. There were 110 patients
ho were receiving statin therapy at the time of their first
vent (death or resuscitated cardiac arrest) or at the end of
he trial for those patients who did not reach the end point
uring the study. The baseline patient characteristics based
n statin therapy at the time of an event or study end are
ummarized in Table 1. There were no significant differ-
nces in baseline characteristics between the 2 groups.
able 1. Demographic Characteristics of Patients Treated With
tatins Versus Those Not Treated With Statins in the 458
atients Enrolled in DEFINITE, Presented as Mean 
tandard Deviation for Continuous Variables and Counts (%)
or Categorical Variables
Not Treated
With Statins
Treated With
Statins p Value
348 110
ge (yrs) 57.7  13.3 60.1  11.5 0.09
ender (female) 103 (29.6%) 29 (26.4%) 0.51
andomized to ICD 172 (49.4%) 57 (51.8%) 0.66
urrent smokers 45 (12.9%) 14 (12.7%) 0.96
ver smokers 151 (43.4%) 42 (38.2%) 0.34
M 73 (21.0%) 32 (29.1%) 0.08
TN 41 (11.8%) 8 (7.3%) 0.18
VEF (%) 21.4  6.0 21.3  6.0 0.95
RS duration (ms) 114.7  29.2 116.12  26.9 0.64
YHA class I 74 (21.3%) 25 (22.7%) 0.75
YHA class II 196 (56.3%) 67 (60.9%) 0.40
YHA class III 78 (22.4%) 18 (16.4%) 0.17
HF duration 1 yr 166 (47.7%) 57 (51.8%) 0.45
eta-blocker 292 (83.9%) 97 (88.2%) 0.28
CE inhibitor/ARB 333 (95.7%) 102 (92.7%) 0.22
spirin 122 (35.1%) 37 (33.6%) 0.79
rrhythmic sudden death 18 (5.2%) 1 (0.9%) 0.04
otal mortality 64 (18.4%) 5 (4.5%) <0.001
old values indicate statistical significance.
ACE  angiotensin-converting enzyme; ARB  angiotensin receptor blocker; CHF
congestive heart failure; DEFINITE  DEFIbrillators in Non-Ischemic cardio-
yopathy Treatment Evaluation; DM  diabetes mellitus; HTN  hypertension;
CD  implantable cardioverter-defibrillator; LVEF  left ventricular ejection
raction; NYHA  New York Heart Association.
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eceiving statin therapy (4.6%) versus 64 deaths in the 348
atients not receiving statin therapy (18.4%; p  0.001).
igure 1 depicts the Kaplan-Meier survival curve for free-
om from death. The unadjusted HR for death among
atients on statin therapy versus those not on statin therapy
as 0.22 (95% CI 0.09 to 0.55; p  0.001).
Using Cox proportional hazards survival models, other
ignificant univariate predictors of death were NYHA
unctional class III (HR 2.14; 95% CI 1.30 to 3.53; p 
.003), diabetes (HR 1.79; 95% CI 1.07 to 3.00; p  0.03),
ypertension (HR 2.34; 95% CI 1.27 to 4.29; p  0.006),
eta-blocker therapy (HR 0.49; 95% CI 0.29 to 0.85; p 
.01), duration of congestive heart failure (CHF) longer
han 1 year (HR 1.62; 95% CI 1.00 to 2.61, p 0.05), QRS
uration (HR 1.01; 95% CI 1.00 to 1.02; p  0.04), and
reatment assignment (HR 0.61; 95% CI 0.38 to 0.99; p 
.04). After accounting for these covariates, statin therapy
emained a significant factor (adjusted HR 0.23; 95% CI
.09 to 0.58; p  0.002). Diabetes and CHF duration were
o longer significant in this multivariate model. When
onsidered along with the effects of statins, ICD therapy
as associated with improved survival (HR 0.61; 95% CI
.38 to 0.99; p  0.04), virtually the same HR reported for
he trial (11). Age, gender, smoking history, ACE inhibitor/
ngiotensin receptor blocker therapy, and aspirin were
ignificant predictors of outcome. Although ACE inhibitor/
ngiotensin receptor blocker therapy was not a significant
ovariate, it should be noted that 95% of patients were on
his therapy; the small sample size of patients not on this
herapy virtually precludes the detection of an effect.
rrhythmic sudden death. There was one arrhythmic
udden death in the 110 patients receiving statin therapy
0.9%) versus 18 arrhythmic sudden deaths in the 348
atients not receiving statin therapy (5.2%; p  0.04).
igure 2 depicts the Kaplan-Meier survival curve for free-
om from an arrhythmic sudden death. The unadjusted HR
igure 1. The Kaplan-Meier estimates of total mortality plus resuscitated
ardiac arrest among patients treated with statins and those not taking
tatins in the 458 patients enrolled in the DEFINITE trial.or arrhythmic sudden death among patients on statin
Bherapy versus those not on statin therapy was 0.16 (95% CI
.022 to 1.21; p  0.08).
Using Cox proportional hazards survival models, we
ound that the only covariate that was significantly related to
he outcome in addition to statin therapy was ICD treat-
ent (HR 0.17; 95% CI 0.05 to 0.60; p 0.005). Although
he regression coefficient for statin therapy remained a
onsignificant factor when modeled along with ICD treat-
ent (HR 0.16; 95% CI 0.02 to 1.21; p  0.08), the
ikelihood ratio test showed that the addition of statin therapy
tatus to the model that already contains ICD treatment
esulted in a significant improvement of model fit (p  0.02).
either age, gender, NYHA functional class, LVEF, QRS
uration, smoking history, diabetes, hypertension, CHF dura-
ion longer than 1 year, beta-blocker therapy, ACE inhibitor/
igure 2. The Kaplan-Meier estimates of arrhythmic sudden death plus
esuscitated cardiac arrest among patients treated with statins and those not
aking statins in the 458 patients enrolled in the DEFINITE trial.
able 2. Demographic Characteristics of Patients Treated With
tatins Versus Those Not Treated With Statins in the 229
atients Enrolled in DEFINITE and Randomized to ICD
herapy, Mean  Standard Deviation for Continuous Variables
nd Counts (%) for Categorical Variables
Not Treated
With Statins
Treated With
Statins
p
Value
173 56
ge (yrs) 57.5  14.1 61.1  12.6 0.10
ender (female) 49 (28.3%) 14 (25.0%) 0.63
urrent smokers 19 (11.0%) 7 (12.5%) 0.76
ver smokers 77 (44.5%) 23 (41.1%) 0.65
M 38 (22.0%) 14 (25.0%) 0.64
TN 22 (12.7%) 3 (5.4%) 0.13
VEF (%) 21.1  5.9 20.1  5.9 0.24
RS duration (ms) 113.9  29.8 117.2  27.1 0.46
YHA class I 43 (24.9%) 15 (26.8%) 0.77
YHA class II 92 (53.2%) 32 (57.1%) 0.61
YHA class III 38 (22.0%) 9 (16.1%) 0.34
HF duration 1 yr 76 (43.9%) 22 (39.3%) 0.54
eta-blocker 147 (85.0%) 49 (87.5%) 0.64
CE inhibitor/ARB 167 (96.5%) 50 (89.3%) 0.03
spirin 62 (35.8%) 21 (37.5%) 0.82
umber with appropriate shocks 27 (15.6%) 7 (12.5%) 0.60old value indicates statistical significance.
Abbreviations as in Table 1.
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September 19, 2006:1228–33 Effects of Statins in Dilated Cardiomyopathyngiotensin receptor blocker therapy, nor aspirin therapy were
ignificant predictors of arrhythmic sudden death.
ppropriate shocks. Of the 229 patients randomized to
eceive an ICD, 56 were receiving statin therapy at the time
f their first appropriate shock or at the end of the trial. The
aseline patient characteristics for this group based on statin
herapy are summarized in Table 2. More patients who were
ot on statin at the time of an arrhythmic event were on
CE inhibitors/angiotensin receptor blockers (96.5%) as
ompared with patients who were on statin therapy (89.3%;
 0.03). There were no other significant differences in
aseline characteristics. There were 7 patients who received
ppropriate shocks among the 56 patients receiving statin
herapy (12.5%) versus 27 patients with appropriate shocks
mong the 173 patients not receiving statin therapy (15.6%;
 0.60 for log-rank test statistic; HR 0.80; 95% CI 0.35
o 1.84; p  0.80). Figure 3 depicts the Kaplan-Meier
urvival curve for freedom from appropriate shocks. The
R for appropriate shocks among patients on statin therapy
ersus those not on statin therapy was 0.78 (95% CI 0.34 to
.82) after adjustment for baseline ACE inhibitor/
ngiotensin receptor blocker therapy status.
Figure 4 shows the distribution of number of shocks each
atient received stratified by statin therapy. Patients who
ere not on statin therapy did not receive multiple shocks
ore frequently than those on statin therapy (15 of 27 or
5.6% vs. 3 of 7 42.9%, p 0.68 via Fisher’s exact test). The
ean number of shocks was 2.1  1.6 shocks for those not
n statin therapy versus 1.7  1.1 shocks for those on statin
herapy (p  0.50). There was no significant difference in
he incidence of inappropriate shocks among those ICD
atients who were treated with statins (21.4%) and those
ot treated with statins (25.4%).
ISCUSSION
he present report demonstrates that statin use in patients
ith nonischemic cardiomyopathy may have dramatic ef-
igure 3. The Kaplan-Meier estimates of appropriate shocks among
atients treated with statins and those not taking statins in the 229
atients randomized to ICD therapy in the 458 patients enrolled in the
EFINITE trial.ects on survival. The observed 78% reduction in mortality
F
pssociated with statin therapy was larger than the benefit
ttributable to ICD therapy in this trial, though there was a
ignificant benefit to ICD therapy even after accounting for
he benefit of statin therapy. The effects of statins on total
ortality are due, in part, to a reduction in arrhythmic
udden death. These findings should be confirmed in a
rospective, randomized clinical trial.
Although the benefit of statin therapy in patients with
oronary artery disease has been well established in multiple
arge-scale randomized clinical trials, only few studies have
ocused on their effects on life threatening ventricular
rrhythmias (7–9) or on patients with nonischemic cardio-
yopathy (4–6,10,13). A number of nonrandomized clin-
cal studies have demonstrated dramatic reduction in ar-
hythmic events in patients who have ICDs inserted. In an
bservational study, DeSutter et al. (7) first reported that in
atients with coronary artery disease receiving ICDs for
econdary prevention of ventricular arrhythmias, treatment
ith lipid-lowering drug therapy (59% statins, 41% fibrates)
esulted in a substantial reduction in appropriate shocks
22% in the group treated with lipid lowering drugs and
7% in those not treated). In another observational study in
atients with coronary artery disease receiving ICDs, Chiu
t al. (8) reported that 30% of patients on statins received
CD therapy versus 50% among those who did not receive
tatin therapy (HR 0.60). In the AVID (Antiarrhythmics
ersus Implantable Defibrillators) trial (9), there was a
eported 0.40 reduction in relative hazard (95% CI 0.15 to
.58) for recurrence of ventricular tachycardia/fibrillation.
Recently, special focus has been given to the effects of
tatins in patients with heart failure as these patients
ypically were not included in the large-scale clinical trials
valuating statin therapy and there are data suggesting an
nverse relationship between cholesterol levels and mortality
n patients with heart failure (14,15). In the PRAISE
Prospective Randomized Amlopidine Survival Evaluation)
rial (16), there was a 62% reduction in total mortality
ttributable to statin therapy. Statin therapy was adminis-
ered to 134 of the 1153 patients in the trial, but only 23igure 4. Distribution of number of appropriate shocks received per
atient in patients treated with statins and those not taking statins.
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Effects of Statins in Dilated Cardiomyopathy September 19, 2006:1228–33atients with nonischemic cardiomyopathy received statins.
n a large cohort study of elderly patients with heart failure
etiology not specified), a 33% reduction in total mortality
as observed in patients treated with statins. Several studies
how that fewer patients develop heart failure when treated
ith statins (17,18). Several small randomized studies (4–6)
f 15 to 108 patients with nonischemic cardiomyopathy
evealed that statin therapy was associated with significant
mprovement in clinical parameters including quality of life,
xercise capacity, NYHA functional class, and LVEF.
inally, Horwich et al. (10) described the outcomes of 551
atients referred to a specialized cardiomyopathy center for
eart failure or transplant evaluation; 55% of the patients
ad a nonischemic cardiomyopathy. Forty-five percent of
he total population was treated with statins, but only 22%
f those with nonischemic cardiomyopathy. There was a
ignificant improvement in 1-year survival without the need
or urgent heart transplantation in patients with nonisch-
mic cardiomyopathy treated with statins. The current
nalysis of the use of statins in patients enrolled in the
EFINITE study further suggests that statin therapy in
atients with nonischemic cardiomyopathy improves sur-
ival. Although some of this benefit is attributable to
eduction in arrhythmic sudden death, the magnitude of its
ffect suggests that there are also other mechanisms for the
mproved survival.
Although statin therapy has been reported to reduce
ppropriate ICD shocks (7–9), these reports have included
nly patients with coronary artery disease. It is interesting to
ote that, in this study, there was no clear reduction in
ppropriate ICD shocks related to statin therapy, despite a
eduction in mortality and arrhythmic sudden death. This
esult could reflect limited power to detect a difference due
o the small sample size (n  229). Alternatively, in this
opulation, appropriate ICD shocks occurred more fre-
uently than sudden cardiac death, suggesting that many of
he arrhythmias may have self-terminated (19). Neverthe-
ess, statin therapy appears to have some effect on arrhyth-
ic sudden death, although not having a detectable effect
n these latter arrhythmias. Finally, statin effects on non-
rrhythmic mortality may be more prominent than the
ffects on arrhythmic mortality. Further studies are necessary
o determine the relative contribution of statin therapy to
mprovement in arrhythmic and non-arrhythmic mortality.
The mechanism for the effects of statins on arrhythmic
udden death and survival in patients with nonischemic
ardiomyopathy remains unclear. An anti-ischemic effect, as
oted in patients with coronary artery disease, is plausible as
substantial proportion of patients with nonischemic car-
iomyopathy are found to have coronary artery disease at
utopsy (20). With regard to antiarrhythmic effects, statins
lso have been reported to be effective in prevention of atrial
brillation (1–3). Finally, as noted previously, the small
tudies that have found improvements in ejection fraction
nd exercise capacity related to statin therapy support the
otion that statins may have beneficial effects on left jentricular remodeling. Thus, it is most likely that statin
herapy exerts multiple beneficial effects in patients with
onischemic cardiomyopathy by its lipid lowering, anti-
nflammatory, antioxidant, autonomic, and/or other ef-
ects (21).
The present findings are particularly notable for the large
ffects attributable to statin therapy, an adjusted HR of 0.22
or total mortality. This occurred in the setting of 85% usage
f beta-blocker therapy and 95% usage of ACE inhibitors or
ngiotensin receptor blockers. On the basis of the available
ata at the time the trial was designed, a 15% 2-year
ortality was postulated with 50% of the deaths being due
o arrhythmia. The observed 2-year mortality in the stan-
ard therapy group was 14.1%, but only one-third of the
eaths were due to arrhythmia. It is possible that the high
requency of statin use may have contributed to the reduced
raction of deaths attributable to arrhythmia.
tudy limitations. Although the present findings are quite
ramatic, they should be considered exploratory and require
onfirmation in a prospective randomized clinical trial.
owever, selection bias as an explanation for the present
ndings is unlikely. First, there are multiple studies that
ocument a relatively large effect of treatment, including
andomized trial data. Second, the presence of a selection
ias would imply that hypercholesterolemia triggering statin
herapy selects a patient population at markedly lower risk
han nonhypercholesterolemic patients, an implausible
ssumption.
Although it is attractive to attribute the findings to the
leiotropic effects of statins, it is possible that the results are
ue to their cholesterol-lowering effects, with the possibility
hat all lipid-lowering agents might provide the same
enefit in patients with nonischemic dilated cardiomyopa-
hy. There were an additional 14 patients on other lipid-
owering agents; including those patients in this analysis did
ot alter the findings. Furthermore, it is unknown whether
atients with nonischemic cardiomyopathy without hyper-
holesterolemia might benefit from statin therapy. Bleske
t al. (13) showed neither a beneficial nor a detrimental
ffect of statin therapy on markers of inflammation, endo-
helial activation, and parasympathetic tone in patients with
eart failure and average low-density lipoprotein levels.
onclusions. Statin therapy has become a mainstay in
atients with coronary artery disease. The combined data from
his trial and the few other clinical studies that have evaluated
he use of statins in nonischemic dilated cardiomyopathy
rovide strong justification for evaluating whether routine
tatin use in this patient population, even those without
ypercholesterolemia, provides a clinical benefit.
eprint requests and correspondence: Dr. Jeffrey Goldberger,
orthwestern University Feinberg School of Medicine, 251 East
uron, Feinberg Pavilion 8-542, Chicago, Illinois 60611. E-mail:-goldberger@northwestern.edu.
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